ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "remission"

  • Abstract Number: 620 • 2016 ACR/ARHP Annual Meeting

    Clinical Activity, Ultrasound Assessment and Drug Monitoring in Rheumatoid Arthritis Patients Receiving Anti-TNF-α Therapy with Extended Interval of Administration

    José Miguel Senabre-Gallego1, José Rosas1, Francisca Llinares-Tello2, Mariana Marco-Mingot2, Ana Pons1, Xavier Barber3, Gregorio Santos-Soler1, Esteban Salas-Heredia1, Catalina Cano1, Marisa Lorente4, Marina Sanchís3, Juan Molina2, Mario García-Carrasco5 and AIRE-MB, 1Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, 2Laboratory, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, 3CIO, Universidad Miguel Hernández, Elche, Spain, 4Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, 5Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR Instituto Mexicano del Seguro Social, Puebla, Mexico

    Background/Purpose:  To assess clinical activity, ultrasound synovitis and drug levels in rheumatoid arthritis (RA) patients receiving anti-TNFα therapy with extended interval of administration (EIA).  Methods:…
  • Abstract Number: 1636 • 2016 ACR/ARHP Annual Meeting

    Decrease of Tocilizumab in Rheumatoid Arthritis in Remission : A Multicenter Study

    Renaud DESBARBIEUX, 59037, CHRU de Lille, Lille, France

    Background/Purpose:  The advent of biological therapies in rheumatoid arthritis has significantly reduced the activity of rheumatoid arthritis, leading to obtaining a remission in a significant…
  • Abstract Number: 1974 • 2016 ACR/ARHP Annual Meeting

    Is Ultrasound of the Hands Enough to Reveal Ongoing Subclinical Inflammation in Rheumatoid Arthritis Patients in Clinical Remission According to Composite Scores?

    Hilde Berner Hammer1, Tore K Kvien2 and Lene Terslev3, 1Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark

    Background/Purpose: Several studies have shown the presence of subclinical inflammation by ultrasound (US) in rheumatoid arthritis (RA) patients despite clinical remission according to clinical composite…
  • Abstract Number: 2487 • 2016 ACR/ARHP Annual Meeting

    In Patients with Rheumatoid Arthritis in Clinical Remission Undergoing Treatment Tapering Tenosynovitis and Synovitis Detected By Ultrasonography Predict Disease Flare

    Antonella Adinolfi1, Giovanni Cagnotto2, Filippo Luccioli3, Claudio Mastaglio4, Giulia Mirabelli3, Daniela Rossi5, Silvia Rossi2, Emanuela Bellis6, Greta Carrara7, Carlo Alberto Scirè8, Annamaria Iagnocco9 and Garifallia Sakellariou2, 1Policlinico le Scotte, Siena, Italy, 2University of Pavia, IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, 3University of Perugia, Perugia, Italy, 4Moriggia-Pelascini, Gravedona, Italy, 5Department of Medicine and Experimental Oncology, CMID - Center of Research of Immunopathology and Rare Diseases, Turin, Italy, 6Rheumatology, Ospedale Mauriziano, Turin, Italy, 7Epidemiology Unit, Italian Society for Rheumatology, Milano, Italy, 8Epidemiology Unit -Italian Society for Rheumatology, Milano, Italy, 9Sapienza University of Rome, Rome, Italy

    Background/Purpose: Ultrasound (US) detected synovitis predicts flare in patients with rheumatoid arthritis (RA), while the role of tenosynovitis has yet to be established. The aim…
  • Abstract Number: 2495 • 2016 ACR/ARHP Annual Meeting

    The Prevalence of Loss of Response to Treatment with a Tumor Necrosis Factor Inhibitor and/or Methotrexate in Patients with Rheumatoid Arthritis

    Josef Smolen1, Yihan Li2, Iain Sainsbury2, Stefan Florentinus2, Kershnie Rambalee2 and GR Burmester3, 1Internal Medicine III, Div. of Rheumatology, Medical University of Vienna, Vienna, Austria, 2AbbVie Inc., North Chicago, IL, 3Charité – University Medicine Berlin, Berlin, Germany

    Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) who achieve disease control in response to treatment with a tumor necrosis factor inhibitor (TNFi) may lose that…
  • Abstract Number: 2512 • 2016 ACR/ARHP Annual Meeting

    Secular Trends of Sustained Remission in Rheumatoid Arthritis, a Nationwide Register Study in Sweden

    Jon T. Einarsson1, Minna Willim1, Sofia Ernestam2, Tore Saxne1, Pierre Geborek1 and Meliha C. Kapetanovic1, 1Lund University, Skane University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, 2Centre of Rheumatology, Stockholm County Council, Stockholm, Sweden, Stockholm, Sweden

      Background/Purpose: Remission has become a treatment goal in rheumatoid arthritis (RA) especially after the introduction of biologic treatment in 1999. The Swedish quality registry…
  • Abstract Number: 2528 • 2016 ACR/ARHP Annual Meeting

    Predictors of Long Term Survival of Low-Dose Etanercept: An Observational Study

    Francesca Ometto1, Bernd Raffeiner2,3, Costantino Botsios2, Davide Astorri4, Lara Friso2, Livio Bernardi5, Leonardo Punzi6 and Andrea Doria2, 1Rheumatology Unit, Department of Medicine - DIMED, University of Padova, PADOVA, Italy, 2Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, 3Rheumatology Unit, Internal Medicine, General Hospital of Bolzano, Bolzano, Italy, 4Rheumatology Unit, Department of Medicine - DIMED, University of Padova, padova, Italy, 5Rheumatology Unit, Department of Medicine -DIMED, University of Padova, PADOVA, Italy, 6Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy

    Background/Purpose: The objective of the study was to investigate long-term survival of low-dose etanercept (ETN) (25 mg weekly) and possible predictors of survival. Methods: We…
  • Abstract Number: 3212 • 2016 ACR/ARHP Annual Meeting

    Treat-to-Target in RA: Does Early Simplified Disease Activity Index (SDAI) Remission Lead to Better 5-Year Functional Outcomes Than SDAI Low Disease Activity?

    Vibeke Norvang, Elisabeth Lie, Inge C Olsen, Eirik K Kristianslund, Tore K Kvien and Till Uhlig, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

    Background/Purpose: The management of rheumatoid arthritis (RA) has evolved considerably during the last couple of decades, with current recommended practice being a treat-to-target approach, involving…
  • Abstract Number: 97 • 2016 ACR/ARHP Annual Meeting

    Effects of DMARD Tapering on Treatment Costs and Work Productivity in Rheumatoid Arthritis Patients- an Analysis from the Prospective Randomized Controlled Retro- Study

    Melanie Hagen1, Camille P Figueiredo2, Jayme Fogagnolo Cobra3, Judith Haschka4, Michaela Reiser5, Matthias Englbrecht6, Axel J. Hueber7, Bernhard Manger6, Arnd Kleyer8, Stephanie Finzel9, Hans-Peter Tony10, Stefan Kleinert11, Joerg Wendler12, Florian Schuch12, Monika Ronneberger12, Martin Feuchtenberger13, Martin Fleck14, Karin Manger15, Wolfgang Ochs16, Matthias Schmitt-Haendle17, H.-M. Lorenz18, HG Nüßlein19, R Alten20, Joerg C. Henes21, Klaus Krüger22, Georg Schett7 and Juergen Rech7, 1Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany, 2Rheumatology Division, Faculdade de Medicina da USP, São Paulo, Brazil, 3Instituto de Reumatologia de Sao Paolo, Sao Paolo, Brazil, 4Medical Department II, St. Vincent Hospital, the VINFORCE Study Group, Academic Teaching Hospital of Medical University of Vienna, Vienna, Austria, Vienna, Austria, 5Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, 6Department of Internal Medicine 3, Rheumatology & Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, 7Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, 8Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, 9Rheumatology and Clinical Immunology, University Medical Center Freiburg, Freiburg, Freiburg, Germany, 10Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany, 11Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Germany, 12Schwerpunktpraxis Rheumatologie, Erlangen, Germany, 13Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, 14Department of Internal Medicine I, University of Regensburg, 93042 Regensburg, Germany, 15Rheumatology Practice Bamberg, Bamberg, Germany, 16Internistisch-rheumatologische Praxisgemeinschaft Bayreuth, Bayreuth, Germany, 17Rheumatology Practice, Bayreuth, Germany, Bayreuth, Germany, 18Im Neuenheimer Feld 41, UNI-Klinikum Heidelberg, Medizinische Klinik,, Heidelberg, Germany, 19University of Erlangen, Nürnberg, Germany, 20Rheumazentrum Ruhrgebiet, Herne, Germany, 21Department of Internal Medicine II, Division of Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, 22Praxiszentrum St. Bonifatius, München, Germany

    Effects of DMARD Tapering on Treatment Costs and Work Productivity in Rheumatoid Arthritis Patients- an Analysis from the Prospective Randomized Controlled RETRO- Study Background/Purpose: Achieving remission…
  • Abstract Number: 132 • 2016 ACR/ARHP Annual Meeting

    Ultrasound Performed Among RA Patients in Real Life Setting Can Predict Loss of Remission, Especially When Done Early after Reaching Remission

    Pascal Zufferey1, Giorgio Tamborrini2, Burkhard Moeller3, Adrian Ciurea4, Laure Brulhart5, Sandra Blumhardt6, Martin Toniolo7 and Hans Ruedi Ziswiler8, 1Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland, 2Bethesda spital, Basel, Switzerland, 3Rheumatology & Clin Immunology, Inselspital Bern, Bern, Switzerland, 4Center of Experimental Rheumatology, University Hospital Zurich, Zurich Schlieren, Switzerland, 5médecine, hôpital neuchateulois, La chaux de fond, Switzerland, 6rheumatology, USZ, zurich, Switzerland, 7Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, 8Osteorheuma, Bern, Switzerland

    Background/Purpose: Previous publications have suggested that patients in clinical remission with residual ultrasound (US) synovitis flare more often and do not stay in remission as long…
  • Abstract Number: 133 • 2016 ACR/ARHP Annual Meeting

    Agreement Between DAS28-ESR, DAS28-CRP, SDAI, CDAI (Simplified/Clinical Disease Activity Index), ACR/EULAR Remission Criteria and Ultrasound Scoring (Naredo-12) in Patients with Rheumatoid Arthritis in Routine Care

    Marion Cugnet1, Mélanie Trabelsi2, Paul Ornetti1, Philippe Gaudin3, Stéphanie Rouanet4 and Athan Baillet2, 1Rheumatology, Dijon University Hospital, France, Dijon, France, 2Rheumatology, Grenoble University Hospital, France, Echirolles, France, 3Grenoble University Hospital, France, Grenoble, France, 4StatEthic, Levallois-Perret, France, Levallois Perret, France

    Background/Purpose: Clinical remission is now a realistic goal in managing rheumatoid arthritis (RA) with treat to target strategy assessed according to different composite scores (DAS28,…
  • Abstract Number: 543 • 2016 ACR/ARHP Annual Meeting

    Synovial Features of Rheumatoid Arthritis and Psoriatic Arthritis Differ in Patients in Clinical and Ultrasound Remission after Anti-TNF Therapy

    Stefano Alivernini1, Luca Petricca1, Laura Bui2, Barbara Tolusso1, Gabriele Di Sante1, Roberta Benvenuto2, Anna Laura Fedele1, Elisa Gremese1 and Gianfranco Ferraccioli1, 1Division of Rheumatology - Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, 2Division of Histopathology - Institute of Pathology, Catholic University of the Sacred Heart, Rome, Italy

    Background/Purpose:  Persistent disease remission is the major goal of Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) treatment. The combined use of clinical and ultrasound selection…
  • Abstract Number: 10L • 2015 ACR/ARHP Annual Meeting

    Aiming for Remission in Rheumatoid Arthritis: Clinical and Radiographic Outcomes from a Randomized Controlled Strategy Trial Investigating the Added Value of Ultrasonography in a Treat-to-Target Regimen

    Espen A. Haavardsholm1, Anna-Birgitte Aga1, Inge C Olsen2, Hilde B. Hammer3, Till Uhlig4, Hallvard Fremstad5, Tor Magne Madland6, Åse S. Lexberg7, Hilde Haukeland8, Erik Rødevand9, Christian Høili10, Hilde Stray11, Anne Noraas Bendvold12, Inger Johanne Widding Hansen13, Gunnstein Bakland14,15, Lena B. Nordberg1, Siri Lillegraven1, Désirée van der Heijde1,16 and Tore K. Kvien1, 1Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Postboks 23 Vinderen, Diakonhjemmet Hospital, Oslo, Norway, 4Diakonhjemmet Hospital, Oslo, Norway, 5Dept. of Rheumatology, Ålesund Hospital, Helse Møre og Romsdal HF, Ålesund, Norway, 6Dept. of Rheumatology, Haukeland University Hospital, Bergen, Norway, 7Dept. of Rheumatology, Vestre Viken Hospital, Drammen, Norway, 8Dept. of Rheumatology, Martina Hansens Hospital, Bærum, Norway, 9Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, 10Dept. of Rheumatology, Hospital Østfold HF, Moss, Norway, 11Haugesund Rheumatism Hospital, Haugesund, Norway, 12The Rheumatology Clinic Dovland/Bendvold, Kristiansand, Norway, 13Dept. of Rheumatology, Sørlandet Hospital, Kristiansand, Norway, 14Dept. of Rheumatology, University Hospital Northern Norway, Tromsø, Norway, 15Institute of Clinical Medicine, University Hospital of North Norway, Tromsø, Norway, 16Dept. of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: The application of ultrasonography (US) in rheumatology clinical practice is growing. The ARCTIC trial (NCT01205854) was designed to examine if the use of a…
  • Abstract Number: 516 • 2015 ACR/ARHP Annual Meeting

    Immunological and Ultrasound Characteristics of Patients with Rheumatoid Arthritis in Clinical Remission – Can We Use These to Predict Outcomes?

    Hanna Gul1, Maria Jesus Isorna Porto2, Elizabeth M.A. Hensor3, Frederique Ponchel4, Richard J. Wakefield5 and Paul Emery6, 1Rheumatology, Leeds Institute of Rheumatology and Musculoskeletal Medicine, Leeds, United Kingdom, 2Internal Medicine, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, 3NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 4Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, 5University of Leeds, Leeds, United Kingdom, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Remission is the key treatment goal in rheumatoid arthritis (RA).  Although clinical remission is increasingly achieved, many patients progress both structurally and functionally. We…
  • Abstract Number: 588 • 2015 ACR/ARHP Annual Meeting

    Prospective Study about Extension of Dosing Interval with Tocilizumab Therapy in Rheumatoid Arthritis Patients in Remission Maintenance

    Jun Kikuchi, Akiko Shibata, Ryota Sakai, Kentaro Chino, Tsuneo Kondo, Ayumi Okuyama, Hirofumi Takei and Koichi Amano, Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan

    Background/Purpose: Tocilizumab (TCZ) is clinically effective against rheumatoid arthritis (RA) and over 50% of RA patients who had completed 5 years of TCZ treatment maintained…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology